WELCOME TO The Biotechnology REPORT
Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...
CELL AND GENE THERAPY
Burixafor | November 09, 2020
TaiGen Biotechnology Company, Limited ("TaiGen") announced today that they have signed an exclusive agreement with GPCR Therapeutics, Inc. ("GPCR"), a leading Korean biotechnology company, for the continued development of Burixafor worldwide and the commercialization of Taigexyn® (nemonoxacin) in South Korea. Burixafor is a highly potent CXCR4 inhibitor currently under clinical development. It can be used as a stem cell mobilizer for hematopoietic stem cell transplantatio...
US Drug Test | July 21, 2020
US Drug Test Centers, one of the largest testing companies in the United States, announced they are now offering COVID-19 Antibody Testing with FDA Emergency Use Authorization at 1,800+ locations nationwide. No prescription is necessary. To book an appointment, visit www.usdrugtestcenters.com, select a location, order a test and an order from a local doctor will be sent to you in 6-12 hours. The test includes a simple blood draw, and results are received usually within 24-48 hours.Antibody...
Provention Bio, Inc. | May 19, 2020
The preclinical prototype vaccine is well-tolerated and provides strong protection against coxsackievirus B infections and diabetes in relevant animal models.
Results provide a solid scientific basis for human trials with Provention's PRV-101 vaccine.
TheDailyTimes | April 15, 2020
Ensysce Biosciences announced that it is exploring the opportunity to initiate a clinical trial of oral Nafamostat, an ingredient from its opioid overdose protection platform, as a treatment for COVID-19. The goal is to evaluate if nafamostat mesylate (Nafamostat), a synthetic protease inhibitor will be effective in preventing or reducing the lethal outcome of COVID-19 infection. Currently, there are no approved drugs to manage infection with SARS-CoV-2 and nafamostat has shown promise in severa...
Keep me plugged in with the best
Join thousands of your peers and receive our weekly newsletter with the latest news, industry events, customer insights, and market intelligence.
Put your news, events, company, and promotional content in front of thousands of your peers and potential customers.
Not a member yet? Not a problem, Sign Up
Sign up to contribute and publish your news, events, brand, and content with the community for FREE